ES2432534T3 - Perfiles metabólicos - Google Patents
Perfiles metabólicos Download PDFInfo
- Publication number
- ES2432534T3 ES2432534T3 ES10710609T ES10710609T ES2432534T3 ES 2432534 T3 ES2432534 T3 ES 2432534T3 ES 10710609 T ES10710609 T ES 10710609T ES 10710609 T ES10710609 T ES 10710609T ES 2432534 T3 ES2432534 T3 ES 2432534T3
- Authority
- ES
- Spain
- Prior art keywords
- metabolites
- endogenous
- subject
- levels
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 35
- 239000002207 metabolite Substances 0.000 claims abstract description 228
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000012472 biological sample Substances 0.000 claims abstract description 56
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- 230000004075 alteration Effects 0.000 claims abstract description 25
- 230000007423 decrease Effects 0.000 claims abstract description 25
- 238000001514 detection method Methods 0.000 claims abstract description 15
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004471 Glycine Substances 0.000 claims abstract description 13
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 13
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 13
- 239000004472 Lysine Substances 0.000 claims abstract description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 13
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004473 Threonine Substances 0.000 claims abstract description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001230 asparagine Drugs 0.000 claims abstract description 13
- 235000009582 asparagine Nutrition 0.000 claims abstract description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960000310 isoleucine Drugs 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930182817 methionine Natural products 0.000 claims abstract description 13
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 18
- 239000008280 blood Substances 0.000 claims description 18
- 238000012544 monitoring process Methods 0.000 claims description 10
- 230000036961 partial effect Effects 0.000 claims description 9
- FGEWTNKUNGVHKT-UHFFFAOYSA-N 2-[(2-chloro-3,4-dimethoxyphenyl)methylideneamino]guanidine Chemical compound COC1=CC=C(C=NNC(N)=N)C(Cl)=C1OC FGEWTNKUNGVHKT-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical group 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000012458 free base Substances 0.000 claims description 7
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 7
- 238000004611 spectroscopical analysis Methods 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 238000012569 chemometric method Methods 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000000513 principal component analysis Methods 0.000 claims description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 210000001179 synovial fluid Anatomy 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000011141 high resolution liquid chromatography Methods 0.000 claims description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 2
- 238000012306 spectroscopic technique Methods 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 238000003745 diagnosis Methods 0.000 description 28
- 208000023275 Autoimmune disease Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 238000000926 separation method Methods 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 19
- 208000009386 Experimental Arthritis Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 206010003246 arthritis Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000003389 potentiating effect Effects 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000003018 immunoassay Methods 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 101000836540 Homo sapiens Aldo-keto reductase family 1 member B1 Proteins 0.000 description 3
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 3
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 3
- 241001596784 Pegasus Species 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000012159 carrier gas Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 102000046818 human AR Human genes 0.000 description 3
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000013515 script Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000006884 silylation reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- -1 thiol compounds Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0905098A GB0905098D0 (en) | 2009-03-24 | 2009-03-24 | Use of biomarkers |
| GB0905096 | 2009-03-24 | ||
| GB0905096A GB0905096D0 (en) | 2009-03-24 | 2009-03-24 | Biomarkers |
| GB0905098 | 2009-03-24 | ||
| GB0905090 | 2009-03-24 | ||
| GB0905090A GB0905090D0 (en) | 2009-03-24 | 2009-03-24 | Biomarkers |
| PCT/GB2010/000557 WO2010109192A1 (en) | 2009-03-24 | 2010-03-24 | Metabolic profiles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2432534T3 true ES2432534T3 (es) | 2013-12-04 |
Family
ID=42228305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10710609T Active ES2432534T3 (es) | 2009-03-24 | 2010-03-24 | Perfiles metabólicos |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20120108668A1 (https=) |
| EP (1) | EP2411812B1 (https=) |
| JP (1) | JP5607719B2 (https=) |
| ES (1) | ES2432534T3 (https=) |
| GB (1) | GB2470803A (https=) |
| WO (1) | WO2010109192A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2470270A1 (en) * | 2009-07-31 | 2012-07-04 | AnaMar AB | Compounds for treatment of inflammation |
| JP6198377B2 (ja) * | 2012-09-14 | 2017-09-20 | キヤノン株式会社 | 表示制御装置、表示制御方法、及びプログラム |
| US20160061812A1 (en) * | 2013-03-15 | 2016-03-03 | The University Of Birmingham | Diagnosis and Treatment of Arthritic Conditions |
| CN103675181A (zh) * | 2013-12-05 | 2014-03-26 | 陈东 | 气相色谱-质谱检测细胞内外液中有机酸、氨基酸、糖的方法 |
| CN106175684B (zh) * | 2016-07-13 | 2018-12-21 | 华南师范大学 | 基于激光光谱技术的人体股骨头病变早期诊断设备及其操作方法 |
| CN109115905A (zh) * | 2018-07-31 | 2019-01-01 | 苏州旭辉检测有限公司 | 一种血液样本中鸟氨酸的检测方法 |
| CN111307792A (zh) * | 2020-02-20 | 2020-06-19 | 江苏大学 | 一种猪肉食源性致病菌挥发性代谢物的色敏仿生传感检测方法 |
| GB202102105D0 (en) * | 2021-02-15 | 2021-03-31 | Novabiotics Ltd | Prognostic method |
| CN115290797A (zh) * | 2022-09-13 | 2022-11-04 | 贵州医科大学 | 基于气质联用技术的黑骨藤抗类风湿性关节炎代谢组学研究方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| WO2005094200A2 (en) | 2003-06-20 | 2005-10-13 | University Of Florida | Biomarkers for differentiating between type 2 and type 2 diabetes |
| US7700364B2 (en) * | 2004-10-12 | 2010-04-20 | Quest Diagnostics Investments Incorporated | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
| WO2006066263A1 (en) | 2004-12-17 | 2006-06-22 | Entelos, Inc. | Assessing insulin resistance using biomarkers |
| EP2339346B1 (en) | 2006-03-24 | 2014-09-03 | Metanomics GmbH | Methods for predicting diabetes type II |
| DE102006026173A1 (de) | 2006-06-06 | 2007-12-20 | Fachhochschule Südwestfalen | Verfahren zur nichtinvasiven Diagnose von Diabetes |
| EP2047278B1 (en) | 2006-07-28 | 2013-01-02 | Gian Franco Bottazzo | Prediction of type 1 diabetes |
| US20090318392A1 (en) | 2006-09-14 | 2009-12-24 | Zora Biosciences Oy | Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk |
| CN101796408B (zh) * | 2007-06-29 | 2014-05-07 | 奎斯特诊断投资公司 | 用液相层析-质谱法分析体液内的氨基酸 |
-
2010
- 2010-03-24 GB GB1004994A patent/GB2470803A/en not_active Withdrawn
- 2010-03-24 WO PCT/GB2010/000557 patent/WO2010109192A1/en not_active Ceased
- 2010-03-24 JP JP2012501376A patent/JP5607719B2/ja not_active Expired - Fee Related
- 2010-03-24 US US13/259,733 patent/US20120108668A1/en not_active Abandoned
- 2010-03-24 ES ES10710609T patent/ES2432534T3/es active Active
- 2010-03-24 EP EP10710609.8A patent/EP2411812B1/en not_active Not-in-force
-
2015
- 2015-07-24 US US14/807,920 patent/US20160018407A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB201004994D0 (en) | 2010-05-12 |
| JP2012521551A (ja) | 2012-09-13 |
| GB2470803A (en) | 2010-12-08 |
| US20160018407A1 (en) | 2016-01-21 |
| EP2411812A1 (en) | 2012-02-01 |
| US20120108668A1 (en) | 2012-05-03 |
| WO2010109192A1 (en) | 2010-09-30 |
| EP2411812B1 (en) | 2013-10-02 |
| JP5607719B2 (ja) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2432534T3 (es) | Perfiles metabólicos | |
| De Jong et al. | Automated mass spectrometric analysis of urinary and plasma serotonin | |
| ES2731678T3 (es) | Herramientas de diagnóstico para la enfermedad de Alzheimer | |
| van Vliet et al. | Dried blood spot versus venous blood sampling for phenylalanine and tyrosine | |
| US20210132071A1 (en) | Detection of cancer biomarkers using nanoparticles | |
| EP2729810B1 (en) | Myositis | |
| Stejskal et al. | Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA | |
| Gilquin et al. | Multiplex and accurate quantification of acute kidney injury biomarker candidates in urine using Protein Standard Absolute Quantification (PSAQ) and targeted proteomics | |
| RU2524641C2 (ru) | Способ детекции дегенеративных мышечных заболеваний и способ определения терапевтической эффективности при заболеваниях | |
| Sanabria et al. | Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma | |
| US20210208165A1 (en) | Protein biomarkers for nephropathy and applications thereof | |
| Bima et al. | Asymmetric and symmetric dimethylarginine as markers of endothelial dysfunction in cerebrovascular disease: A prospective study | |
| Day et al. | Fecal M2-PK in children with Crohn’s disease: a preliminary report | |
| Pesakova et al. | Liquid chromatography-tandem mass spectrometry method for determination of total and free teriflunomide concentration in serum of patients with multiple sclerosis | |
| Chen et al. | Discovery of potential biomarkers in acute kidney injury by ultra-high-performance liquid chromatography-tandem quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF–MS) | |
| Janzen et al. | UPLC–MS/MS analysis of C5-acylcarnitines in dried blood spots | |
| Xing et al. | A metabolic profiling analysis of the nephrotoxicity of acyclovir in rats using ultra performance liquid chromatography/mass spectrometry | |
| Yan et al. | Targeted metabolomics-based understanding of the sleep disturbances in drug-naïve patients with schizophrenia | |
| CN108896771B (zh) | Guca2a蛋白在骨关节炎中的用途 | |
| Larimore et al. | Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity | |
| Ma et al. | Simultaneous determination of colistin sulfate and tigecycline in human plasma by liquid chromatography-tandem mass spectrometry method | |
| Dierkes et al. | Fenofibrate increases the L-arginine: ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration | |
| Kumar et al. | Preclinical pharmacokinetic exploration of a novel osteoporotic quinazolinone-benzopyran-indole hybrid (S019-0385) using LC-MS/MS | |
| Saita et al. | Development of an enzyme-linked immunosorbent assay for the quantification of O-Phosphoethanolamine in human plasma | |
| Lee et al. | Molecular architecture of mouse and human pancreatic zymogen granules: protein components and their copy numbers |